Simply put, our mission is to drive greater good.

At every level in our company, our singular focus is to deliver value through safe, effective and affordable biopharmaceuticals, starting with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer and psoriasis. Not only will these medications provide critical, often life-saving benefit to patients at favorable cost, they will profit our shareholders, staff, and partner and payer communities as well. Our aim is to deliver end-to-end advantage, benefiting all stakeholders throughout our value chain.

In 1984, Dr. Allen Chao helped ignite a revolution in healthcare as a pioneer in the off-patent “generic” drug industry. As the founder and visionary of Watson Pharmaceuticals, he had a mission to drive down the cost of prescription drugs and extend their availability to millions of patients who otherwise couldn’t afford the medications they needed. In just ten years, from 2005 -2014, generics are estimated to have saved our healthcare system over $1.68 Trillion* – more than $3 Billion a week.

*Generic Drug Savings in the U.S., 2015 Edition, Generic Pharmaceutical Association

More than thirty years later, the revolution continues at Tanvex BioPharma. Here, Dr. Chao and his dedicated and talented team are applying the same passion, experience and expertise for improving the availability and affordability of pharmaceuticals to a new generation of drugs: biopharmaceuticals, including biologics and their non-branded, off-patent drug equivalents, biosimilars.

Producing biologics and biosimilars in sufficiently large quantities, while maintaining quality and consistency, is a complex challenge that has contributed to their high cost. Today, through more efficient in-house, end-to-end manufacturing and innovative, patent-pending processes, Tanvex BioPharma is revolutionizing the biopharmaceutical industry. We offer a truly, fully vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from R&D and cell-line development, Tanvex BioPharma can achieve enviable quality and consistency, and respond with unparalleled agility to rapidly changing market and regulatory demands.

Tanvex BioPharma is at the forefront of this emerging industry, poised to repeat the success of Dr. Chao’s first company, Watson Pharmaceuticals, this time revolutionizing the biopharmaceutical space by developing and delivering safe, effective, and affordable biologic and biosimilar drugs to the people whose lives depend upon them.

As a global business, Tanvex BioPharma has successfully united operating teams in Taiwan and the United States, a strategy that provides efficiencies, scale, and multi-faceted scientific thinking.

From the outset, our approach has been strategic: Build a company that can sustain itself over time; execute with agility and persistence; quickly respond to regulatory changes and opportunity; attract, nurture and grow stellar talent; respect the environment; and create and deliver value to every stakeholder.

Our culture prizes creative thinking and innovation in pursuit of continuous improvement and excellence. Our multi-product facility meets stringent global regulatory requirements and utilizes the latest “green” technologies, affording maximum flexibility, rapid turnaround times, and reduced cost and time to market. Purpose-built, our infrastructure supports the company’s microbial and mammalian cell line development, process development, and Current Good Manufacturing Practice (cGMP) capabilities.

Tanvex BioPharma is a vertically integrated company, with end-to-end capabilities from R&D through to commercialization, well funded and unencumbered by partnership or contractual agreements that can create drag or inertia.

Mammalian and microbial cell line development and characterization, master cell selection and cell “seeds” are produced in the company’s Taiwan-based lab.

Second generation upstream development takes place in the U.S. facility, where working cell banks are grown and reproduced in quantity, and monitored for stability, expression level, and the physical and biologic properties most similar to the reference products, preparatory to harvest. Investments in high-volume production facilities, microbial fermenters and mammalian bioreactors ensure the ability to scale quickly for product commercialization.

Downstream activities including purification and packaging take place in-house in the U.S. plant. The facility also incorporates warehouse space for storage of product prior to distribution.

Combined with its executional model, this gives Tanvex BioPharma unprecedented self-reliance, control and flexibility, for a unique competitive advantage.